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Abstract
Introduction:  Oral  squamous  cell  carcinoma  (OSCC)  is  a  serious  public  health  problem,  due
to its  high  mortality  rate  and  worldwide  rising  incidence.  OSCC  susceptibility  is  mediated  by
interactions  between  genetic  and  environmental  factors.  Studies  suggest  that  genetic  vari-
ants encoding  enzymes  involved  in  folate  metabolism  may  modulate  OSCC  risk  by  altering  DNA
synthesis/repair  and  methylation  process.
Objective:  The  goals  of  this  study  were  to  evaluate  the  association  of  three  genotypic  polymor-
phism (MTHFR  C677T,  MTHFR  A1298C  and  CBS  844ins68)  and  oral  cancer  risk  in  southeastern
Brazilians and  evaluate  the  interactions  between  polymorphisms  and  clinical  histopathological
parameters.
Methods:  This  case--control  study  included  101  cases  and  102  controls  in  the  state  of  Espírito
Santo, Brazil.  MTHFR  genotyping  was  done  by  PCR-RFLP  (polymerase  chain  reaction  --  restric-
tion fragment  length  polymorphism)  and  CBS  genotyping  by  PCR  (polymerase  chain  reaction)
analysis.
 Please cite this article as: Barbosa A, dos Santos M, de Podestá JR, Gouvêa SA, Von Zeidler SV, Louro ID, et al. Polymorphisms in
ethylenetetrahydrofolate reductase and cystathionine beta-synthase in oral cancer -- a case--control study in southeastern Brazilians. Braz
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Results:  MTHFR  C677T  polymorphism  was  associated  with  lymph  node  involvement.  Genotype
CT +  TT  acted  as  a  protective  factor.  MTHFR  A1298C  AC  +  CC  genotype  was  associated  with
tumor differentiation,  and  possibly  with  a  better  prognosis.  In  risk  analysis,  no  correlation
was observed  between  genotypes  and  OSCC.
Conclusion:  We  concluded  that  MTHFR  C677T,  MTHFR  A1298C  and  CBS  844ins68  polymorphisms
were not  associated  with  OSCC  risk  in  southeastern  Brazilians;  however,  we  suggest  a  prognosis
effect associated  with  MTHFR  C677T  and  A1298C  polymorphisms  in  OSCC.
© 2015  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published
by Elsevier  Editora  Ltda.  This  is  an  open  access  article  under  the  CC  BY  license  (http://
creativecommons.org/licenses/by/4.0/).
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Polimorﬁsmos  em  metilenotetrahidrofolato  redutase,  cistationina  beta-sintase
no  câncer  de  boca  --  um  estudo  de  caso-controle  no  Sudeste  brasileiro
Resumo
Introduc¸ão:  O  carcinoma  espinocelular  oral  (CECO)  trata-se  de  um  importante  problema  de
saúde pública,  devido  à  elevada  taxa  de  mortalidade  e  incidência  crescente  em  todo  o  mundo.
A susceptibilidade  ao  CECO  é  mediada  por  interac¸ões  entre  fatores  genéticos  e  ambientais.  Estu-
dos sugerem  que  as  variantes  genéticas  que  codiﬁcam  as  enzimas  envolvidas  no  metabolismo
do folato  podem  modular  o  risco  de  CECO,  alterando  a  síntese/reparac¸ão  do  DNA  e  o  processo
de metilac¸ão.
Objetivo:  Os  objetivos  deste  estudo  foram  avaliar  a  associac¸ão  de  três  polimorﬁsmos
genotípicos  (MTHFR  C677T,  MTHFR  A1298C  e  CBS  844ins68)  e  o  risco  de  câncer  bucal  em
brasileiros da  região  Sudeste,  e  avaliar  as  interac¸ões  entre  polimorﬁsmos  e  parâmetros  clínico-
histopatológicos.
Método: Este  estudo  de  caso-controle  incluiu  101  casos  e  102  controles  no  estado  do  Espírito
Santo, Brasil.  A  genotipagem  do  polimorﬁsmo  MTHFR  foi  realizada  por  PCR-RFLP  (Reac¸ão  de
Polimerase em  Cadeia  --  Polimorﬁsmo  no  Comprimento  de  Fragmento  de  Restric¸ão)  e  a  do  CBS
por análise  da  PCR  (Reac¸ão  de  Polimerase  em  Cadeia).
Resultados:  O  polimorﬁsmo  MTHFR  C677T  foi  associado  ao  envolvimento  de  gânglios  linfáticos.
O genótipo  CT  +  TT  atuou  como  um  fator  protetor.  O  genótipo  MTHFR  A1298C  AC  +  CC  foi  associ-
ado à  diferenciac¸ão  do  tumor  e,  possivelmente,  a  um  prognóstico  melhor.  Na  análise  de  risco,
a correlac¸ão  entre  os  genótipos  e  o  CECO  não  foi  observada.
Conclusão:  Concluímos  que  os  polimorﬁsmos  MTHFR  C677T,  MTHFR  A1298C  e  CBS  844ins68  não
estão associados  ao  risco  de  CECO  nos  brasileiros  da  região  Sudeste;  no  entanto,  sugerimos  um
efeito prognóstico  associado  aos  polimorﬁsmos  MTHFR  C677T  e  A1298C  em  CECO.
© 2015  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado
por Elsevier  Editora  Ltda.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY  (http://
creativecommons.org/licenses/by/4.0/).
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Oral  squamous  cell  carcinoma  (OSCC)  is  the  eighth  most
common  human  cancer  worldwide.1 In  Brazil,  nearly  15,290
new  cases  of  oral  cancer  are  expected  in  2014,  and  in  the
Southeast  it  is  the  fourth  among  men  and  tenth  among
women.2 OSCC  is  a  multifactorial  disease,  affected  by  noto-
rious  environmental  factors  such  as  alcohol  and  tobacco,  as
well  as  genetic  factors,  of  which  little  is  known.  Polymor-
phisms  in  certain  genes  may  confer  susceptibility  to  OSCC
development.  Studies  have  shown  a  relationship  between
polymorphisms  of  genes  involved  in  folate  metabolism  and
OSCC  risk  due  to  their  inﬂuence  on  methylation,  synthesis
and  DNA  repair.3--7
A
r
t
RMTHFR  gene  encodes  the  methylenetetrahydrofolate
eductase  enzyme,  that  is  important  for  intracellu-
ar  folate  homeostasis  and  the  irreversible  conversion
f  5,10-methylenetetrahydrofolate  (5,10-MTHF)  into  5-
ethyltetrahydrofolate  (5-MTHF).  Polymorphisms  C677T
nd  A1298C  in  the  MTHFR  gene  may  be  associated  with  oral
ancer  susceptibility  due  to  changes  in  catalytic  activity.  The
677T  polymorphism  results  in  an  enzyme  with  65  percent  of
he  wild-type  homozygote  activity  for  heterozygotes  and  30
ercent  for  homozygotes  of  the  variant  allele.8,9 The  MTHFR
1298C  polymorphism  is  localized  in  the  regulatory  domain
egion.10 Homozygous  1298C  individuals  have  approximately
he  same  enzyme  activity  of  those  who  are  heterozygous.11
educed  MTHFR  enzyme  activity  increases  the  availability
5o
D
a
c
p
i
f
a
c
S
o
M
S
I
f
n
H
s
s
m
m
a
i
t
f
w
a
w
r
p
i
a
p
p
g
r
n
v
r
l
t
T
a
(
s
h
r
o
G
G
t
w
t
p
n
w
d
t
u
p
i
(
(
restriction  site.
Wild  genotype  (AA)  produced  ﬁve  fragments  of  56,  31,
30,  28  and  18  bp,  whereas  heterozygous  (AC)  yielded  six
Table  1  Clinical  characteristics  of  cancer  patients  and  con-
trol subjects.
Characteristics  Patients  Controls  p-value
n (%)  n  (%)
Gender
Female  20  (19.8)  20  (19.6)  0.972
Male 81  (80.2)  82  (80.4)
Age, years
≤55  47  (46.5)  56  (54.9)  0.233
>55 54  (53.5)  46  (45.1)
Ethnic  group
Whites  22  (31.9)  --  --
‘‘Pardos’’
(mixed race)
32  (46.4)  --
Blacks  15  (21.7) --
Tobacco  exposure
Consumer  73  (72.3)  0  (0.0)  --
Non-consumer  28  (27.7)  0  (0.0)
Unknowna 0  (0.0)  102  (100.0)
Tumor  stage
Early  stage  (I,  II)  25  (24.7)  --  --
Advanced  (III,
IV)
76  (75.3)  --
Tumor  sizec
T1  12  (11.9)  --  --
T2 22  (21.8)  --
T3 17  (16.8)  --
T4 50  (49.5)  --
Nodal statusc
N0  50  (49.5)  --  --
N+ 51  (50.5)  --
Histopathological  grade
Well  25  (24.7)  --  --
Moderately  29  (28.7)  --
Poorly  5  (5.0)  --
Not availableb 42  (41.6)  --60  
f  folate  for  the  production  of  thymidylate  and  purine  for
NA  synthesis  and  repair.12
The  CBS  gene  encodes  cystathionine  beta  synthase  (CBS),
lso  involved  in  the  folate  pathway,  which  mediates  the
onversion  of  homocysteine  to  cystathionine.  CBS  844ins68
olymorphism  has  been  associated  with  shorter  survival  time
n  head  and  neck  squamous  cell  carcinoma  patients.13 There-
ore,  this  study  aimed  to  investigate  the  frequency  and
ssociation  of  MTHFR  and  CBS  polymorphisms  in  oral  can-
er  susceptibility  in  the  population  of  the  state  of  Espírito
anto,  Brazil  and  its  potential  impact  on  the  prognostic
utcome.
ethods
amples
n  this  case--control  study,  blood  samples  were  collected
rom  101  patients  with  conclusive  histopathological  diag-
ostic  of  oral  squamous  cell  carcinoma  obtained  from  the
ead  and  Neck  Division  of  the  Hospital  Santa  Rita  de  Cás-
ia,  Brazil.  Of  this  total,  69  individuals  were  classiﬁed  by
kin  color  and  other  physical  traits:  22  as  white  (Caucasians,
ainly  Portuguese  descendents);  32  as  ‘‘pardos’’  (ethnic
ixture  of  Europeans,  Africans  and  Amerindians),  and  15
s  black  (African  descendants),  based  on  the  ofﬁcial  Brazil-
an  census  categorization.  All  patients  were  residents  of
he  state  Espírito  Santo  (ES,  Brazil)  and  randomly  recruited
rom  2011  to  2013.  The  inclusion  criteria  during  this  study
ere  patients  of  both  genders,  over  35  years  of  age  who
ccepted  to  participate  in  the  study.  The  exclusion  criteria
ere  patients  with  SCC  in  other  sites  and  those  who  received
adiotherapy,  chemotherapy,  surgery  or  any  other  treatment
rior  to  recruitment.
The  control  group  was  composed  by  102  individuals  resid-
ng  in  ES,  Brazil,  who  were  referred  for  clinical  assessment
nd  had  a  negative  cancer  familial  history  and  did  not  show
re-malignant  or  malignant  oral  lesions  at  the  time  of  sam-
le  collection.  The  control  group  was  matched  by  age  and
ender.  As  only  partial  data  was  available  for  the  controls
egarding  the  habits  such  smoking  and  alcohol  usage,  it  was
ot  included  for  matching  with  the  cases.  All  subjects  pro-
ided  signed  informed  consents  approved  by  institutional
eview  boards.  This  work  was  previously  approved  by  the
ocal  research  ethics  committee  (CEP  Protocol  n◦ 318/2011).
Clinicopathological  features  of  patients  analyzed  were
umor  stage  (early  stage  I--II  and  late  stage  III--IV),  size  (T1,
2,  T3  and  T4),  nodal  status  (positive  N+  and  negative  N0)
ccording  to  TNM  Classiﬁcation,14 histolopathological  grade
well,  moderately  and  poorly  differentiated  tumors)15 and
moking  habit.  All  required  information  about  clinical  and
istopathological  parameters  was  obtained  from  medical
ecords.  Participants  were  not  classiﬁed  into  ethnic  groups
r  skin  color.
enotyping  assaysenomic  DNA  was  isolated  by  phenol-chloroform  extrac-
ion.  The  MTHFR  C677T  and  MTHFR  A1298C  polymorphisms
ere  genotyped  by  the  PCR-RFLP  (polymerase  chain  reac-
ion  --  restriction  fragment  length  polymorphism)  method,  asBarbosa  A  et  al.
reviously  described.8,11 All  reactions  included  positive  and
egative  controls.  Approximately  20  percent  of  the  samples
ere  randomly  selected  to  repeat  the  genotyping  proce-
ure.  The  reproducibility  was  100  percent.
The  C  →  T  transition  creates  a  restriction  site  for
he  enzyme  Hinf  I.  PCR  product  (198  bp)  was  digested
sing  Hinf1  and  visualized  by  electrophoresis  in  8  percent
olyacrylamide  gels  and  silver  nitrate  staining.  PCR  products
ncluded  a  single  198  bp  fragment  for  wild-type  homozygotes
CC);  198  bp,  175  bp  and  23  bp  fragments  for  heterozygote
CT),  and  175  and  23  bp  for  mutant  homozygote  (TT).
The  MTHFR  1298AC  polymorphism  eliminates  the  MboIITotal 101  (49.8)  102  (50.2)
a Unknown (not considered in the statistical calculations).
b Not available (not considered in the statistical calculations).
c TNM classiﬁcation.
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Table  2  Distribution  of  MTHFR  and  CBS  genotypes  among  oral  cancer  patients  and  control  groups.
Genotypes  Total  Patients  Controls  p-value
n (%)  n  (%)  n  (%)
MTHFR  C677T
CC  100  (49.2)  50  (49.5)  50  (49.0)  0.438
CT 86  (42.4)  45  (44.6)  41  (40.2)
TT 17  (8.4)  6  (5.9)  11  (10.8)
MTHFR A1298C
AA 113  (55.7)  60  (59.4)  53  (52.0)  0.541
AC 80  (39.4) 36  (35.6)  44  (43.1)
CC 10  (4.9) 5  (5.0) 5  (4.9)
CBS 844ins68
NN  163  (80.3)  76  (75.2)  87  (85.3)  0.112
NI 38  (18.7)  24  (23.8)  14  (13.7)
II 2  (1.0)  1  1
Total 203  (100.0)  101  (49.8)  102  (50.2)
2
a
R
C
a
w
8
T
p
a
aN, non-insertion; I, insertion.
fragments  of  84,  56,  31,  30,  28  and  18  bp,  and  homozygous
mutants  (CC)  produced  four  fragments  of  84,  31,  30  and
18  bp.
CBS  844ins68  polymorphisms  were  characterized  by
differential  size  separation  after  PCR,  as  previously
described.16 The  polymorphic  allele  results  from  the  inser-
tion  of  68  bp  at  exon  8.  The  major  allele  (I)  presented  a
239  bp  fragment,  and  the  normal  allele  (N)  presented  a
171  bp  fragment.
Statistical  analysis
Genotypic  frequencies  were  tested  for  Hardy--Weinberg
equilibrium  (HWE).  The  chi-square  and  Fisher  exact  tests
were  used  for  association  analysis,  and  conﬁrmation  was
obtained  by  the  Lilliefors  test  (signiﬁcance  considered  when
p  <  0.05).  Multivariate  logistic  regression  was  used  to  obtain
odds  ratio  (OR)  and  conﬁdence  intervals  (95%  CI).  Statistical
calculations  were  performed  using  the  Epi  InfoH  v  3.4.3,
c
a
h
Table  3  Distribution  of  MTHFR  and  CBS  alleles  among  the  oral  ca
Allele  Patients  
n  (%)  HWE  
2 p-value  
MTHFR  C677T
C 145  (71.8)  1.006  0.316  
T 57  (28.2)  
MTHFR  A1298C
A 156  (77.2)  0.018  0.893  
C 46  (22.8)  
CBS 844ins68
N  176  (87.1)  0.357  0.550  
I 26  (12.9)  
HWE, Hardy--Weinberg equilibrium; 2, chi-square; N, non-insertion; I,007  software.  Linkage  disequilibrium  (LD)  and  halotype
nalysis  were  conducted  by  Haploview  software.
esults
haracteristics  of  101  oral  cancer  patients  and  102  controls
re  shown  in  Table  1.  Signiﬁcant  differences  between  groups
ere  not  observed  (p  >  0.05).
Genotype  frequencies  for  MTHFR  C677T,  A1298C  and  CBS
44ins68  in  controls  and  oral  cancer  patients  are  shown  in
able  2.
Genotype  distribution  of  the  three  genetic  polymor-
hisms  was  not  signiﬁcantly  different  between  oral  cancer
nd  control  group  (p  >  0.05)  (Table  2).  MTHFR  C677T,  A1298C
nd  CBS  844ins68  allele  frequencies  in  controls  and  oral  can-
er  patients  are  shown  in  Table  3. All  tested  polymorphisms
re  in  the  HWE.
Haplo  View  software  was  used  for  conducted  LD  and
aplotype  analysis  on  alleles  of  MTHFR  C677T  and  A1298C
ncer  patients  and  control  groups.
Controls  p-value
n  (%)  HWE
2 p-value
141  (69.1)  0.348  0.555  0.556
63  (30.9)
150  (73.5)  1.193  0.275  0.387
54  (26.5)
188  (92.2)  0.260  0.610  0.096
16  (7.8)
 insertion.
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Table  4  Linkage  disequilibrium  and  haplotype  analysis  for  alleles  of  C677T  and  A1298C  polymorphisms.
Haplotype  Cases
2n  =  202
Controls
2n  =  204
2 p-value  OR  (95%  CI)
C-A  301  291  --  --  1
C-C 191  195  0.173  0.676  0.946  (0.817--1.364)
T-A 231  213  0.141  0.706  1.048  (0.745--1.220)
T-C 103  117  1.040  0.307  0.851  (0.861--1.602)
Table  5  Clinicopathological  characteristics  of  patients  with  OSCC  and  relation  with  the  MTHFR  polymorphisms  studied.
Features  MTHFR  C677T  genotype
CC  CT  TT  p-value  CT  +  TT  p-value
n (%) n  (%) n  (%) n  (%)
Tumor  stage
Early  stage  (I,  II)  12  (24.0)  11  (24.4)  2  (33.3)  0.880  13  (25.5)  0.862
Advanced (III,  IV)  38  (76.0)  34  (75.6)  4  (66.7)  38  (74.5)
Tumor sizea
T1  5  (10.0)  5  (11.1)  2  (33.3)  0.569  7  (13.7)  0.716
T2 12  (24.0)  10  (22.2)  0  (0.0)  10  (19.6)
T3 10  (20.0)  6  (13.3)  1  (16.7)  7  (13.7)
T4 23  (46.0)  24  (53.3)  3  (50.0)  27  (52.9)
Nodal statusa
N0  19  (38.0)  28  (62.2)  3  (50.0)  0.062  31  (60.8)  0.022
N+ 31  (62.0)  17  (37.8)  3  (50.0)  20  (39.2)
Histopathological  grade
Well  10  (20.0)  15  (33.3)  0  (0.0)  0.192  15  (29.4)  0.238
Moderately 12  (24.0)  14  (31.1)  3  (50.0)  17  (33.3)
Poorly 4  (8.0)  1  (2.2)  0  (0.0)  1  (2.0)
Not available b 24  (48.0)  15  (33.3)  3  (50.0)  18  (35.3)
Features MTHFR  A1298C  genotype
AA  AC  CC  p-value  AC  +  CC  p-value
n (%)  n  (%)  n  (%)  n  (%)
Tumor  stage
Early  stage  (I,  II)  14  (23.3)  10  (27.8)  1  (20.0)  0.860  11  (26.8)  0.689
Advanced (III,  IV)  46  (76.7)  26  (72.2)  4  (80.0)  30  (73.2)
Tumor sizea
T1  6  (10.0)  6  (16.7)  0  (0.0)  0.747  6  (14.6)  0.512
T2 16  (26.7)  5  (13.9)  1  (20.0)  6  (14.6)
T3 10  (16.7)  6  (16.7)  1  (20.0)  7  (17.1)
T4 28  (46.7)  19  (52.8)  3  (60.0)  22  (53.7)
Nodal statusa
N0  30  (50.0)  19  (52.8)  1  (20.0)  0.386  20  (48.8)  0.904
N+ 30  (50.0)  17  (47.2)  4  (80.0)  21  (51.2)
Histopathological  grade
Well  8  (13.3)  14  (38.9)  3  (60.0)  0.037  17  (41.5)  0.007
Moderately 18  (30.0)  10  (27.8)  1  (20.0)  11  (26.8)
Poorly 5  (8.3)  0  (0.0)  0  (0.0)  0  (0.0)
Not availableb 29  (48.3)  12  (33.3)  1  (20.0)  13  (31.7)
a TNM classiﬁcation.
b Not available (not considered in the statistical calculations).
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Table  7  Multivariate  analysis  of  the  nodal  status,  according
to tumor  size  and  MTHFR  C677T  polymorphism.
Nodal  status  (N)a
Variable  Multivariate  analysis
OR  (95%  CI)  p-value
Tumor  size  (T)a
T1,  T2 1
T3  3.07  (0.87--10.87) 0.083
T4 6.46  (2.32--17.95) <0.001
MTHFR  C677T
CC 1
CT +  TT  0.32  (0.13--0.77)  0.012
b
(
D
F
aMTHFR  and  CBS  polymorphisms  and  oral  cancer  
polymorphisms  (Table  4).  We  found  that  there  was  no  differ-
ence  for  the  haplotypes  in  the  two  groups  (p  >  0.05),  which
suggested  that  the  haplotypes  do  not  increase  the  risk  of
cancer.
Patients  were  evaluated  by  ethnicity,  but  a  prevalence
of  polymorphic  allele  in  ethnic  groups  was  not  observed.
The  prevalence  of  the  C  allele  (MTHFR  C677T  polymorphism)
was  higher  in  the  three  ethnic  groups  (white  --  63.6  per-
cent;  black  --  73.3  percent,  and  ‘‘pardos’’  --  82.8  percent).
For  the  MTHFR  A1298C  polymorphism,  the  A  allele  predom-
inated  in  all  ethnic  groups  (white  --  72.7  percent;  black  --
83.3  percent,  and  ‘‘pardos’’  --  76.6  percent),  and  ﬁnally,  the
presence  of  the  wild-type  allele  for  CBS  844ins68  polymor-
phism  was  also  more  prevalent  in  all  ethnic  groups  (white  --
86.4  percent;  black  --  86.7  percent,  and  ‘‘pardos’’  --  89.1
percent).  These  data  demonstrate  the  ample  mixture  of
races  in  the  case  group.
Interaction  between  genotypes  and  clinicopathological
features  was  further  analyzed  (Tables  5  and  6).  MTHFR
C677T  polymorphism  is  associated  with  positive  lymph
nodes,  and  the  combination  of  CT  +  TT  genotypes  acts  as
a  protective  factor.  Multivariate  analysis  (95%  CI)  consid-
ering  tumor  size  revealed  that  the  combination  of  CT  +  TT
genotypes  generates  a  risk  of  lymph  node  metastasis
three  times  smaller  than  the  CC  genotype  (p  =  0.012)
(Table  7).
We  observed  that  the  A1298C  polymorphism  is  related
to  tumor  differentiation.  AC  +  CC  genotypes  were  more
frequent  in  well-differentiated  tumors,  whereas  the  AA
genotype  was  more  frequent  in  moderately  or  poorly  dif-
ferentiated  tumors  (p  =  0.007)  (Table  5).
Table  6  Clinicopathological  characteristics  of  patients
with OSCC  and  relation  with  the  CBS  polymorphism  studied.
Features  CBS  844ins68  genotype
Non-insertion  Insertion  p-value
n  (%) n  (%)
Tumor  stage
Early  stage
(I,  II)
18  (23.7)  7  (28.0)  0.664
Advanced
(III, IV)
58  (76.3)  18  (72.0)
Tumor  sizea
T1  8  (10.5)  4  (16.0)  0.792
T2 18  (23.7)  4  (16.0)
T3 13  (17.1)  4  (16.0)
T4 37  (48.7)  13  (52.0)
Nodal  statusa
N0  40  (52.6)  10  (40.0)  0.273
N+ 36  (47.4)  15  (60.0)
Histopathological  grade
Well  19  (25.0)  6  (24.0)  0.462
Moderately  22  (28.9)  7  (28.0)
Poorly  5  (6.6)  0  (0.0)
Not  availableb 30  (39.5)  12  (48.0)
a TNM classiﬁcation.
b Not available (not considered in the statistical calculations).
f
c
M
b
p
(
b
t
l
S
c
t
t
s
r
g
t
t
A
t
g
n
c
s
c
h
L
t
c
m
wOR, odds ratio; CI, conﬁdence interval.
a TNM classiﬁcation.
There  was  no  statistically  signiﬁcant  association
etween  CBS  844ins68  polymorphism  and  analyzed  variables
Table  6).
iscussion
olate  deﬁciency  has  been  associated  with  diseases  such
s  cancer.  Therefore,  the  role  of  genetic  polymorphisms  of
olate  metabolism  enzymes  has  been  investigated  in  several
ancer  types.17,18 Among  these  enzymes,  we  investigated
THFR  and  CBS  in  OSCC.
Our  study  has  reported  for  the  ﬁrst  time  the  association
etween  lymph  node  metastasis  and  MTHFR  C677T  polymor-
hism  combination  CT  + TT,  acting  as  a  protective  factor
p  =  0.022).  Furthermore,  other  studies  have  suggested  a
etter  prognosis  for  oral  cancer  patients  with  CT  or  TT  geno-
ypes.  Tsai  et  al.19 showed  that  677CT  +  TT  patients  had  a
ower  risk  of  metastasis  compared  with  those  with  CC,  and
ailasree  et  al.20 showed  improved  survival.
The  protective  effect  could  be  due  to  its  decreased  efﬁ-
iency  for  DNA  methylation.21 MTHFR  converts  5,10-MTHF
o  5-MTHF.  The  5,10-MTHF  is  used  for  conversion  of  dUMP
o  dTMP,  whereas  5-MTHF  is  the  methyl  donor  for  synthe-
is  of  methionine  and  S-adenosylmethionine  in  methylation
eactions.22 Individuals  with  MTHFR  677TT  and  MTHFR  677CT
enotypes  show  enzymes  with  decreased  activity,8 hence
hey  tend  to  accumulate  5,10-MTHF  causing  a  change  in
he  pathway,  leading  to  lowering  of  DNA  methylation.21
 low  level  of  genomic  DNA  methylation  could  decrease
he  chance  of  promoter  hypermethylation  in  cancer-related
enes  and  lead  to  fewer  mutations  by  spontaneous  deami-
ation  of  5-methylcytosine  (5mC).  Hypermethylation  favors
ancer  initiation  and  progression  by  silencing  tumor  suppres-
or  genes  or  DNA  repair  genes.23 Most  mutations  found  in
ancers  are  C  →  T  transitions  at  CG:CG  sequences,  due  to
igh  frequencies  of  spontaneous  deamination  of  5  mC.24,25
ack  of  cytosine  methylation  could  prevent  C  →  T  muta-
ions.In  addition,  the  MTHFR  A1298C  polymorphism  was  asso-
iated  with  tumor  differentiation.  AC  +  CC  genotypes  were
ore  frequent  in  well-differentiated  tumors  (p  =  0.007),
hich  may  also  be  associated  with  a  better  prognosis,  while
5t
p
o
s
m
s
e
i
l
a
d
u
C
o
n
o
t
w
v
a
p
t
a
t
e
r
o
d
o
a
(
r
o
n
t
I
w
T
q
C
r
d
B
o
A
a
o
P
l
o
p
7
(
t
i
8
h
C
I
c
f
a
c
t
m
C
T
A
A
H
E
R
164  
he  AA  genotype  had  a  higher  frequency  in  moderately  or
oorly  differentiated  tumors.  Although  the  prognostic  value
f  the  histological  grade  is  controversial  in  OSCC,  some
tudies  have  suggested  that  poorly  differentiated  carcino-
as  tend  to  metastasize  and  are  associated  with  decreased
urvival  rates.26 However,  there  is  no  consensus  in  the  lit-
rature  about  whether  histological  tumor  grading  is  a good
solated  parameter  of  prognosis  value.  Tumor  histopatho-
ogical  grade,  together  with  additional  prognostic  factors
nd  TNM  staging  might  provide  better  support  for  treatment
ecision.
However,  in  this  study  with  a  southeastern  Brazilian  pop-
lation,  we  did  not  observe  association  between  MTHFR
677T,  MTHFR  A1298C  and  CBS  844ins68  polymorphisms  and
ral  cancer  susceptibility.  Some  studies  have  also  found  a
on-signiﬁcant  reduced  risk  for  MTHFR  677TT  genotype  in
ral  cancer.27,28 In  contrast,  Sailasree  et  al.20 had  found
hat  C677T  was  associated  with  predisposition  to  oral  cancer
ith  a  signiﬁcant  reduced  risk  for  CT  +  TT  genotype  indi-
iduals.  Meta-analysis  studies29,30 have  shown  a  marginal
ssociation  or  no  associations  of  MTHFR  C677T  polymor-
hism  with  oral  cancer  risk.  The  conﬂicting  results  regarding
he  associations  between  MTHFR  C677T  polymorphisms
nd  risks  for  OSCC  may  be  due  to  different  ethnici-
ies,  subtypes  and  regional  dietary  and  local  carcinogens’
xposure.
For  A1298C  polymorphism,  some  studies  agree  with  our
esults,  including  a  meta-analysis  study19,20,31 showing  a  lack
f  association  with  oral  cancer  risk.  However,  meta-analysis
emonstrated  that  C  allele  has  a  possible  preventive  role  for
ral  cancer.29
In  our  study,  the  CBS  68  bp  insertion  allele  (I)  was  neither
ssociated  with  OSCC  risk  nor  with  heterozygous  genotype
I/N)  or  polymorphic  homozygous  genotype  (I/I),  corrobo-
ating  the  results  of  Galbiatti  et  al.,32 but  unlike  results  for
ther  tumor  types  such  as  prostate  and  upper  gastrointesti-
al  tract  cancers.33,34
MTHFR  C677T  polymorphism  genotype  prevalence  varies
o  a  great  extent  among  different  human  populations.  In
ndians,  the  frequency  of  TT  genotype  is  below  1  percent,20
hereas  among  Mexicans,  it  is  above  30  percent;  the
T  genotype  in  our  controls  showed  a  10.8  percent  fre-
uency,  which  is  comparable  to  previous  reports  from
hinese  and  Puerto  Rican  populations,27,35--37 and  also  in
egions  of  Brazil.38--40 The  frequencies  of  TT  genotype
emonstrated  in  studies  with  populations  in  southeastern
razil  range  from  4.4  percent  to  14  percent  in  the  state
f  São  Paulo.39,41,42 Control  prevalence  of  variant  MTHFR
1298C  genotypes  (CC)  in  our  study  was  4.9  percent,  in
greement  with  studies  in  northeastern  Brazil  and  also  in
ther  populations  of  the  world,  such  as  Chinese,  Japanese,
olish,  Italian  and  Americans19,43--48;  however,  there  was
ittle  difference  from  frequencies  observed  in  the  state
f  São  Paulo,  with  frequencies  of  6.1  percent  and  8.8
ercent.41,42
In  our  study,  the  CBS  68  bp  insertion  allele  (I)  was  found  in
.8  percent  of  the  control  population.  A  similar  frequency
7%)  was  observed  in  the  Pakistani  population49;  however,
he  allelic  frequency  was  higher  in  another  study  conducted
n  São  Paulo,  Brazil.32 As  found  in  another  study,32 CBS
44ins68  polymorphism  was  not  associated  with  clinical  or
istopathological  features  in  our  study.
1Barbosa  A  et  al.
onclusion
n  conclusion,  MTHFR  C677T  CT  and  TT  genotypes  were  asso-
iated  with  lymph  node  involvement,  acting  as  a  protective
actor  in  OSCC,  and  the  MTHFR  A1298C  AC  +  CC  genotype  was
ssociated  with  tumor  differentiation,  which  may  be  asso-
iated  with  a  better  prognosis.  However,  the  results  need
o  be  conﬁrmed  in  larger  studies  of  patients  and  controls
atched  by  smoking  habit.
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